IL85609A - Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation - Google Patents

Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation

Info

Publication number
IL85609A
IL85609A IL85609A IL8560988A IL85609A IL 85609 A IL85609 A IL 85609A IL 85609 A IL85609 A IL 85609A IL 8560988 A IL8560988 A IL 8560988A IL 85609 A IL85609 A IL 85609A
Authority
IL
Israel
Prior art keywords
ethyl
phenyl
carbamate
dimethylamino
salts
Prior art date
Application number
IL85609A
Other languages
English (en)
Other versions
IL85609A0 (en
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL85609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL85609A0 publication Critical patent/IL85609A0/xx
Publication of IL85609A publication Critical patent/IL85609A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL85609A 1987-03-04 1988-03-02 Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation IL85609A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (2)

Publication Number Publication Date
IL85609A0 IL85609A0 (en) 1988-08-31
IL85609A true IL85609A (en) 1992-07-15

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
IL85609A IL85609A (en) 1987-03-04 1988-03-02 Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation

Country Status (29)

Country Link
US (1) US5602176A (2)
JP (3) JP2625478B2 (2)
KR (1) KR0133686B1 (2)
AT (1) AT394190B (2)
AU (1) AU618949B2 (2)
BE (1) BE1001467A3 (2)
CA (1) CA1307003C (2)
CH (1) CH675720A5 (2)
CS (1) CS411091A3 (2)
CY (1) CY1735A (2)
DK (1) DK175762B1 (2)
ES (1) ES2010527A6 (2)
FI (1) FI89165C (2)
FR (1) FR2611707B1 (2)
GB (1) GB2203040C (2)
GR (1) GR1000023B (2)
HK (1) HK110093A (2)
HU (1) HU201906B (2)
IE (1) IE61714B1 (2)
IL (1) IL85609A (2)
IT (1) IT1219853B (2)
LU (2) LU87150A1 (2)
MY (1) MY103225A (2)
NL (1) NL195004C (2)
NZ (1) NZ223714A (2)
PT (1) PT86875B (2)
SA (1) SA93140384B1 (2)
SE (1) SE8800731L (2)
ZA (1) ZA881584B (2)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
AU2224195A (en) * 1994-04-15 1995-11-10 Masaomi Iyo Medicinal composition for treating tardive dyskinesia and utilization thereof
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
WO1998026775A1 (en) * 1996-12-18 1998-06-25 Teva Pharmaceutical Industries, Ltd. Phenylethylamine derivatives
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
EP1121104B1 (en) 1998-10-01 2005-01-12 Novartis AG New controlled release oral formulations for rivastigmine
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
AU2354400A (en) * 1998-12-11 2000-06-26 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US7795307B2 (en) * 2003-10-21 2010-09-14 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
JP4954886B2 (ja) * 2004-11-08 2012-06-20 エムキュア ファーマシューティカルズ リミテッド （ｓ）−３−［（１−ジメチルアミノ）エチル］−フェニル−ｎ−エチル−ｎ−メチル−カルバミン酸の効率的製造方法
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
ATE546202T1 (de) 2005-09-15 2012-03-15 Sony Computer Entertainment Inc Kabelloser videospielcontroller und verfahren zum betreiben des kabellosen videospielcontrollers
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
AU2006326642B2 (en) * 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008020452A1 (en) * 2006-08-17 2008-02-21 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
JP2010518010A (ja) * 2007-02-02 2010-05-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害する化合物
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
AU2008276459A1 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
CN101910110B (zh) * 2008-01-10 2013-05-22 上海医药工业研究院 利凡斯的明的制备方法、其中间体以及中间体的制备方法
WO2010023535A1 (en) 2008-08-25 2010-03-04 Jubilant Organosys Limited A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
BR112012017168B1 (pt) 2009-12-22 2022-03-15 Luye Pharma Ag Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
AU2011215870B2 (en) * 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2793580A1 (en) 2010-03-29 2011-10-06 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
HUE038434T2 (hu) 2010-06-17 2018-10-29 Codexis Inc Biokatalizátorok és módszerek (S)-3(1-aminoetil)-fenol szintéziséhez
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
RS54173B1 (sr) 2010-12-14 2015-12-31 Acino Ag Transdermalni terapijski sistem za davanje aktivne supstance
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
WO2012161489A2 (ko) 2011-05-20 2012-11-29 에스케이케미칼 주식회사 리바스티그민 함유 패취
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
WO2013031992A1 (ja) 2011-08-31 2013-03-07 積水メディカル株式会社 貼付剤
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
MX392119B (es) 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法
CN121772912A (zh) 2023-08-11 2026-03-31 迈图高新材料公司 医药胶粘剂组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
LU90297I2 (fr) 1998-12-07
BE1001467A3 (fr) 1989-11-07
JP2625478B2 (ja) 1997-07-02
NL195004C (nl) 2003-11-04
NL8800436A (nl) 1988-10-03
HUT49325A (en) 1989-09-28
FR2611707A1 (fr) 1988-09-09
IE61714B1 (en) 1994-11-30
CA1307003C (en) 1992-09-01
CY1735A (en) 1994-06-03
GB2203040B (en) 1990-10-24
US5602176A (en) 1997-02-11
MY103225A (en) 1993-05-29
FI89165B (fi) 1993-05-14
ZA881584B (en) 1989-11-29
PT86875B (pt) 1992-05-29
KR0133686B1 (ko) 1998-04-21
GR1000023B (el) 1990-01-31
PT86875A (pt) 1988-04-01
KR880011088A (ko) 1988-10-26
NL195004B (nl) 2003-07-01
ATA55188A (de) 1991-08-15
SE8800731A0 (sv) 1988-09-05
JPS63238054A (ja) 1988-10-04
FI880972L (fi) 1988-09-05
IT8847693A0 (it) 1988-03-04
ES2010527A6 (es) 1989-11-16
CS411091A3 (en) 1992-12-16
IL85609A0 (en) 1988-08-31
IT1219853B (it) 1990-05-24
HU201906B (en) 1991-01-28
GB8804888D0 (en) 1988-03-30
DK112588A (da) 1988-09-05
FR2611707B1 (fr) 1990-04-20
SE8800731D0 (sv) 1988-03-02
SE8800731L (sv) 1988-09-05
CH675720A5 (2) 1990-10-31
GB2203040A (en) 1988-10-12
FI89165C (fi) 1993-08-25
HK110093A (en) 1993-10-29
DK112588D0 (da) 1988-03-02
NZ223714A (en) 1994-05-26
JPH09165362A (ja) 1997-06-24
IE880583L (en) 1988-09-04
GR880100125A (en) 1989-01-31
LU87150A1 (fr) 1988-11-17
AT394190B (de) 1992-02-10
GB2203040C (en) 2014-07-30
FI880972A0 (fi) 1988-03-02
SA93140384B1 (ar) 2006-04-04
DK175762B1 (da) 2005-02-14
AU1255488A (en) 1988-09-08
JPH09118617A (ja) 1997-05-06
JP2859225B2 (ja) 1999-02-17
AU618949B2 (en) 1992-01-16

Similar Documents

Publication Publication Date Title
IL85609A (en) Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation
EP0236624A3 (en) Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them
IL62018A0 (en) Agmatine derivatives,their preparation and pharmaceutical compositions containing them
HUT40143A (en) Process for preparing n,n-dialkyl-guanidino-dipeptide derivatives and pharmaceutical compositions containing thereof as active substances
IL87080A (en) 4-amino-5-halo 2,n-disubstituted benzamides,their preparation and pharmaceutical compositions containing them
PT84737A (en) N-(2(-aminophenyl)-benzamide derivatives process for the preparation thereof and pharmaceutical compositions containing them
IL75197A0 (en) Aminotetralin derivatives,their preparation and pharmaceutical compositions containing them
IL59425A (en) Pharmaceutical compositions comprising n-substituted aziridine-2-carboxylic acid derivatives,certain such compounds and their preparation
GB2053909B (en) Pyrrolidinylalkycarboxylic acid amide derivatives their preparation and pharmaceutical compositions containing them
IL83432A0 (en) Phenyl butenamide derivatives,their preparation and pharmaceutical compositions containing them
IL71185A (en) Pharmaceutical compositions comprising n-(piperidinyl-alkyl))carboxamides,some such novel compounds and their preparation
IL80106A0 (en) Arylmethylazoles and their salts,processes for their preparation and pharmaceutical compositions containing them
IL73427A0 (en) Oxazolidine derivatives,their preparation and pharmaceutical compositions containing them
IL86244A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
IL75794A (en) 2-hydroxy-5-(1-hydroxy-2-(aralkyloxyalkylamino)ethyl)aniline derivatives,their preparation and pharmaceutical compositions containing them
IL73811A (en) N-phenyl-n,n'-dialkylamino-guanidine derivatives,their preparation and pharmaceutical compositions containing them
GB2064514B (en) Flavan compounds and acid addition salts thereof and pharmaceutical compositions thereof
IL79469A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
IL79792A (en) Amino acid derivatives,their preparation and pharmaceutical compositions containing them
IL88446A0 (en) Substituted hydroxylamines,their preparation and pharmaceutical compositions containing them
IL86411A0 (en) Catecholamine derivatives,their preparation and pharmaceutical compositions containing them
IL66227A (en) N-(2-(5-dimethylaminomethyl-furan-2-yl-methylthio)-ethyl)-benzamide derivatives and their salts,their preparation and pharmaceutical compositions containing them
PH15697A (en) 2-acetoxymethyl-2-methyl-(5r)-penam-3a-carboxylic acid,base salts thereof and pharmaceutical compositions containing same
IL68872A0 (en) N-(2-methoxyethyl)-noroxymorphone and salts thereof,their preparation and pharmaceutical compositions containing them
ZA803466B (en) (3 - alkylamino - 2 - hydroxypropoxy) - furan - 2 - carboxxlic acid anilides and physiologically tolerated acid addition salts thereof, processes for their preparation, and medicaments containing them

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)
KB Patent renewed
PEL Intention of commissioner to extend period of protection
EXTG Extension of patent term granted
EXTG Extension of patent term granted
KB Patent renewed
EXTN Extension order renewed
EXTN Extension order renewed
EXP Patent expired